Biomarker-Based Disease Detection Market - Strategic Insights and Forecasts (2026-2031)

The Biomarker-Based Disease Detection market is projected to grow at a CAGR of 11.0%, attaining USD 107.1 billion in 2031 from USD 63.5 billion in 2026.

The biomarker-based disease detection market enables early disease diagnosis, prognosis, and personalized therapy by identifying genetic, proteomic, or metabolic markers. Adoption is driven by rising chronic disease prevalence, precision medicine initiatives, and technological advances in molecular diagnostics. Hospitals, research institutions, and pharmaceutical companies increasingly rely on biomarker testing for improved patient outcomes.

Description

Tests that use biomarkers to measure the progress of a disease or the effectiveness of treatment, including gene mutations, proteins, metabolites, and epigenetic factors. These are used primarily in cancer or tumor treatment (oncology), heart disease (cardiology), brain disease (neurology), and various infections (infectious disease); a wide range of applications exists for these tests. Innovative and improved technologies, including the use of next-generation sequencing, mass spectrometry, immunoassays, and AI to analyse test results, have improved the turnaround time, sensitivity, and accuracy of biomarker testing. In addition to continuous growth coming from government funding to promote precision medicine and the adoption of companion diagnostics, many tests are currently being developed as part of point-of-care testing devices or will be used in lab settings where large numbers of patients can be tested. The rapid growth in the number of patients with chronic conditions and the increased demand for customised therapies are also increasing the adoption of biomarker testing in hospitals, laboratories, and pharmaceutical companies around the world.

Biomarker-Based Disease Detection Market Analysis

Growth Drivers

·      Increased Burden of Chronic Disease: The increasing prevalence and incidence of chronic diseases, such as cancer, cardiovascular disease, and neurological disease, have created a growing need for biomarker-based testing. Early identification of patients with these chronic diseases and accurate identification of their respective conditions will improve the ability to provide precise treatment, reduce the risk of adverse events associated with prescribed medications, and facilitate the development of individualised therapy. For this reason, biomarkers have become a required component of modern healthcare.

·      Advancements in High-Throughput Technologies: Advanced sequencing technologies, mass spectrometry, and immunoassays that provide high-throughput capabilities can be used to analyse multiple biomarkers simultaneously. The use of high-throughput technologies has helped improve the efficiency, accuracy, and scalability of biomarker testing, thus enabling greater acceptance of biomarker testing in clinical practice and research.

·      Precision Medicine Initiatives: National and international initiatives focused on promoting the use of genotype- and biomarker-guided therapy have encouraged increased adoption of biomarker detection platforms. The development of clinical practice guidelines based on the use of evidence-based clinical practices is also becoming more common, as healthcare providers recognize that biomarker testing can be helpful in optimizing drug selection and ultimately improving patient outcomes.

·      Government and Regulatory Support: Government funding for biomarker discovery, development of companion diagnostics, and clinical validation will help drive the growth of the biomarker testing market. Additionally, government support of quality, safety, and standardization measures through the establishment of regulatory pathways will promote acceptance and use of biomarker testing in hospitals, diagnostic laboratories, and pharmaceutical companies.

Challenges and Opportunities

·      The biomarker-based disease detection market faces challenges such as high assay development costs, complex multi-marker data interpretation, and limited standardization across laboratories. Regulatory compliance, data privacy, and reproducibility issues can slow clinical adoption. However, strong opportunities exist through multi-analyte panels, AI-driven analytics, and integration with point-of-care platforms. Precision medicine initiatives, collaborations with pharmaceutical companies, and rising chronic disease prevalence further support growth. Emerging markets, particularly in Asia-Pacific and Latin America, are expanding due to improving healthcare infrastructure. As validated biomarkers increase and technology advances, early diagnosis and personalized therapy adoption are expected to rise, driving long-term market growth.

Key Development

·      October 2025: Illumina, Inc. officially launched its 5-Base solution, a novel sequencing platform that enables simultaneous detection of both genomic variants and DNA methylation from a single sample workflow. The solution uses proprietary 5-base chemistry and enhanced DRAGEN analysis to deliver high-resolution insights into both the methylome and genome, streamlining epigenetic and genetic analysis for research and clinical applications. This development improves efficiency and reduces costs for epigenetic diagnostics, particularly in oncology and rare disease biomarker discovery, and positions dual-omic testing as a scalable solution for clinical labs

Market Segmentation

The market is segmented by product type, technology, application and geography.

By Product Type: Reagents & Kits

Kits & reagents have historically been the backbone of epigenetics testing and offer a wide variety of ‘ready to use’ assay kits for the following areas: DNA methylation, histone modification, and chromatin analysis. Laboratories utilize these kits & reagents because they minimize variability, reduce time required to perform tests and standardise procedures across research and clinical environments. With the continued expansion of diagnostic laboratories into molecular and precision medicine testing, there is establishing a continued increase in the demand for validated, high sensitivity kits & reagents; this is particularly true where reproducibility is paramount, such as in oncology-related diagnostic panels.

By Technology: Next-Generation Sequencing (NGS)

NGS leads the technology segment as it enables comprehensive multi-gene and multi-biomarker analysis with high sensitivity and accuracy. It is particularly preferred in oncology and complex disease diagnostics, supporting personalized therapy and companion diagnostic development.

By Application: Oncology

Many cancers are caused not only by genetic mutations but also by epigenetic changes. Biomarker-based tests aid early cancer detection, prognosis, therapy selection, and monitoring, improving patient outcomes and supporting personalised treatment approaches in clinical settings.

Regional Analysis

North America Market Analysis

North America has a lead in the biomarker-based disease diagnostic industry principally because of its well-developed health care system, strong regulations supporting medical innovation; and a high rate of adoption of precision medicine technologies. The U.S. FDA plays an important role in expediting approvals for companion diagnostics and encourages the use of biomarkers in routine clinical practice, particularly within the context of hormone-based treatments. The widespread adoption of hospitals, collaborative research programs, and payer reimbursement mechanisms aids the expansion of this sector. Canada has additional support for biomarkers through their investment in research grants for genomic and biomarker-related projects. Investment by many of the major players in diagnostics and their presence through investment in high-throughput molecular technologies further contributes to the region's leadership position in the market.

South America Market Analysis

South America, consisting of Brazil, Argentina, and Chile, currently leads the region in terms of adoption of biomarker-based diagnostics, as robust academic research networks and government-funded genomics programmes have provided access to these tests across the region. Although limitations of infrastructure and reimbursement have impeded the widespread adoption of biomarker-based diagnostics across the region, increasing levels of adoption across oncology, cardiovascular, and infectious disease testing have recently occurred.

Europe Market Analysis

Europe has a growing base of biomarker-based disease diagnostics supported by guidelines from the EMA, national healthcare initiatives promoting precision medicine, and increasing numbers of clinical studies utilising biomarker testing. For example, the introduction of GDPR compliant data protection legislation has increased the pace of cross-border research, which continues to contribute to the rapid adoption of biomarker technologies. In addition, Germany, the UK and France have published reimbursement pathways that further facilitate access to biomarkers and speed their adoption for clinical use. By financing collaborative projects through Horizon Europe, the development and broad application of biomarkers will be further enhanced.

Middle East and Africa Market Analysis

The Middle East and Africa are in the early stages of adopting biomarker-based detection; recent growth has been driven by government investment into modernising healthcare and implementing precision medicine programmes. Implementation of biomarker-based diagnostics is principally being driven by private hospitals and research institutions, and through collaborative partnerships with international diagnostic companies that support the implementation process.

Asia Pacific Market Analysis

Asia-Pacific is currently the fastest growing region due to government sponsored genomics programs, the increasing prevalence of prevalent chronic diseases, and improving hospital infrastructure. In this region, China, Japan, South Korea and India have made significant investments both in diagnostic capabilities and in the research needed to further develop biomarker-based tests. To implement biomarker-based testing in oncology and cardiovascular diseases, urban hospitals, academic research centres and collaborative projects with pharmaceutical companies provide the majority of support. In addition to technological investments, increasing clinical recognition and usage of biomarker-based testing, and the use of private healthcare will further support continued long-term expansion of this market.

List of Companies

·      Roche Diagnostics

·      Thermo Fisher Scientific

·      Illumina

·      Agilent Technologies

·      QIAGEN

·      Bio-Rad Laboratories

·      PerkinElmer

·      Diagenode

·      Active Motif

·      Abcam

Roche Diagnostics

Within its product offerings, one can find real-time PCR systems, high-throughput testing solutions, and companion diagnostics used for oncological, infectious diseases, and genetic testing. Its diagnostic technology facilitates laboratory automation and collaboration through integration with laboratory information systems, allowing for optimal workflows and data management. Roche also manufactures multiplex assays to enable the simultaneous detection of various pathogens. Furthermore, Roche's continuous investments in new technologies, including next-generation sequencing and biomarker discovery, are helping to solidify its role in the field of precision medicine. The breadth of Roche's portfolio and its global reach establish it as one of the leading diagnostic companies, helping to make it an essential component of clinical and reference labs.

Thermo Fisher Scientific

Thermo Fisher's Applied Biosystems brand manufactures and sells products that relate to genetic analysis, infectious disease identification, and research purposes. Additionally, Thermo Fisher's platforms provide high-throughput workflows, allowing labs to increase their testing capacity. Thermo Fisher also offers package solutions for integrated service/support to help labs achieve optimal assay performance and compliance. Thermo Fisher is well-known for its strong commitment to research and development in order to support ongoing innovation in testing and laboratory automation, positioning it to be a critical partner for clinical and research labs globally.